Stryker (SYK) Q3 2024 earnings summary

Executive summary

• Achieved 11.9% year-over-year sales growth in Q3 2024, with organic sales up 11.5% and double-digit gains in both U.S. and international markets.

• MedSurg and Neurotechnology, as well as Orthopaedics and Spine, delivered strong performances, with Medical, Neurotechnology, Trauma & Extremities, Hips, and Knees all posting double-digit organic growth.

• Completed seven acquisitions year-to-date, investing $1.6 billion upfront and $395 million in contingent consideration, including care.ai, NICO Corporation, and Vertos Medical.

• Adjusted EPS for Q3 was $2.87, up 16.7% year-over-year; reported EPS was $2.16.

• Issued $1.5 billion and €1.4 billion in new senior unsecured notes in September 2024.

Financial highlights

• Q3 net sales were $5.5 billion, up 11.9% year-over-year; nine months net sales reached $16.2 billion, up 10.1%.

• Adjusted EPS was $2.87, a 16.7% increase year-over-year; adjusted net earnings for Q3 reached $1.1 billion.

• Adjusted operating margin reached 24.7% of sales, up 130 basis points from Q3 2023.

• Adjusted gross margin was 64.5%, down 20 basis points year-over-year; reported gross margin was 64.0%.

• Year-to-date cash from operations was $2.3 billion, up $120 million from 2023.

Outlook and guidance

• Full-year 2024 organic sales growth expected at 9.5%-10%, with adjusted EPS of $12.00-$12.10, reflecting a $0.10 negative impact from foreign exchange.

• Guidance reflects continued product innovation, healthy procedure volumes, and strong commercial execution.

• Targeting 200 basis points of margin expansion by end of 2025, including 100 basis points in 2024.

• Acquisitions in 2024 expected to contribute approximately $300 million to 2025 sales.

• Monitoring potential impacts from new global tax laws and regulatory changes.